Brief: Triton3 Phase 3 Trial Of Rubraca Meets Primary Endpoint In Men With A Type of Prostate Cancer
03/10/2022 12:19
Oct 3 (Reuters) - Clovis Oncology Inc CLVS.O :
* TRITON3 PHASE 3 TRIAL OF RUBRACA® (RUCAPARIB) ACHIEVES
PRIMARY
ENDPOINT IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE
CANCER WITH BRCA OR ATM MUTATIONS
* CLOVIS ONCOLOGY INC - SAFETY PROFILE OF RUBRACA OBSERVED
IN
TRITON3 WAS CONSISTENT WITH RUBRACA LABELLING
* CLOVIS ONCOLOGY INC -TRITON3 WILL SERVE AS BASIS OF
SUPPLEMENTAL
NEW DRUG APPLICATION FOR US LABEL EXPANSION TO BE SUBMITTED
DURING Q1 2023
Source text for Eikon: ID:nBwb9YKHqa
Further company coverage: CLVS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clovis Oncology
See all newsBrief: Clovis Oncology Inc - On April 5, 2023, Entered Into Asset Purchase Agreement With Pharma& To Sell Product Business For Upfront Payment Of $70 Million
Brief: Clovis Oncology Enters Into Financing Agreement
Brief: Clovis Oncology Inc Received Written Notice From Nasdaq That Company's Common Stock Will Be Delisted From Nasdaq
U.S. STOCKS ON THE MOVE-Nike, Faraday Future, PBF Energy
U.S. STOCKS ON THE MOVE-Natural gas, Box Inc, Weber